AKP.F Anika Therapeutics Inc

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
12.30 EUR
Close of Nov 12, 2026
7.00 18.50
Market cap
EUR 165M
P/E
-
P/B
1.38x
ROE
-2.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AKP.F undervalued?

Graham number

The Graham number of Anika Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anika Therapeutics Inc fundamental analysis

No fundamental analysis for Anika Therapeutics Inc yet.

Anika Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, inclu…

Full company profile